The FDA approved Klygefa for myasthenia gravis on 16 November 2026, clearing AstraZeneca and Alexion’s gefurulimab-gaks for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. Klygefa is a once-weekly complement C5 inhibitor that patients inject themselves with an autoinjector. In the 260-patient PREVAIL Phase III trial it improved daily-living scores by 1.6 points more than placebo at 26 weeks, with benefit seen from the first week.
Key takeaways on Klygefa for myasthenia gravis
- Approved for adults with AChR antibody-positive gMG, a group that makes up about 85% of gMG patients.
- Gefurulimab is a dual-binding nanobody: one end blocks C5, the other binds albumin to stretch its half-life to weekly dosing.
- PREVAIL met its primary endpoint (MG-ADL difference of 1.6 points, p<0.0001) and key secondary QMG endpoint.
- Like other C5 blockers, it carries a boxed warning for meningococcal infection and is available only through a REMS program.
- Klygefa is already approved in the EU and Japan; China and other markets are reviewing it.
The PREVAIL results in numbers
PREVAIL randomized 260 adults across 20 countries 1:1 to Klygefa or placebo, on top of standard therapy, for a 26-week double-blind period. Results were published in JAMA Neurology.
| Endpoint at week 26 | Klygefa | Placebo | Difference |
|---|---|---|---|
| MG-ADL change (primary) | -4.2 | -2.6 | 1.6 points (p<0.0001) |
| QMG change (key secondary) | -4.5 | -2.4 | 2.1 points (p<0.001) |
| QMG responders (5+ point gain) | 46.3% | 25.2% | 21.1 points, by our calculation |
| Any treatment-emergent adverse event | 75.6% | 80.6% | Similar |
| Injection-site reactions | 9.9% | 3.1% | Higher on Klygefa |
MG-ADL is a patient-reported scale covering chewing, swallowing, speech, breathing, eyelid drooping, double vision and limb weakness; a 2-point change is commonly treated as clinically meaningful for an individual patient. A 1.6-point average gap over placebo is in line with other approved gMG biologics, and the near-doubling of QMG responders gives a clearer sense of how many patients see a meaningful gain. Improvement in MG-ADL appeared by week one and held through week 26.
How a nanobody gets to weekly dosing
In AChR-positive gMG, autoantibodies attack receptors at the junction between nerve and muscle and switch on the complement cascade, which damages the muscle membrane. Blocking C5, near the end of that cascade, stops the formation of the membrane attack complex. Alexion’s earlier C5 antibodies, Soliris (eculizumab) and Ultomiris (ravulizumab), are given by intravenous infusion every two to eight weeks, and UCB’s Zilbrysq (zilucoplan) is a daily self-injected C5 peptide.
Gefurulimab takes a different engineering route. Nanobodies are small single-domain antibody fragments that normally clear from the blood quickly. By building in a second binding arm that latches onto serum albumin, the body’s most abundant blood protein, the drug piggybacks on albumin’s long circulation time. Alexion describes it as the first and only dual-binding nanobody C5 inhibitor approved in the U.S. The result is a weight-based loading dose on day 1, then weekly maintenance from day 8, self-administered under the skin.
Safety and the REMS requirement
Terminal complement blockade raises the risk of infection with Neisseria meningitidis. Klygefa’s label carries a boxed warning, and the drug can only be prescribed through the Klygefa REMS. Patients must be vaccinated against meningococcal disease at least two weeks before the first dose and carry a patient safety card during treatment and for three months afterward. No meningococcal infections were seen in PREVAIL’s randomized period.
Across the full clinical program, AstraZeneca reported two fatal infections (dengue fever and sepsis from a dental infection) and three serious cases of diverticulitis with intestinal perforation. The most common side effect was injection-site reaction, at about 12% in the label. Investigator Kelly Gwathmey noted that “gMG is a disease marked by unpredictability and variability,” which is why a steady weekly option may appeal to some patients.
Where Klygefa fits among gMG treatments
- IV C5 inhibitors: Soliris and Ultomiris, requiring infusion visits.
- Daily self-injected C5: Zilbrysq.
- FcRn blockers: argenx’s Vyvgart Hytrulo and UCB’s Rystiggo, which lower pathogenic antibodies rather than block complement. Our report on argenx’s efgartigimod setback in Sjögren’s shows how this class is faring outside gMG.
- Klygefa: weekly, self-injected, complement-targeted, positioned as a home-based alternative to infusions.
About 98,500 Americans have been diagnosed with gMG, roughly 81,000 of them AChR-positive, according to AstraZeneca. Price and the U.S. launch date have not been announced. For Indian patients, no CDSCO filing has been disclosed; AstraZeneca lists China and other markets as under review.
Market context
According to Acumen Research and Consulting, the global myasthenia gravis treatment market was valued at USD 1.3 billion in 2022 and is projected to reach USD 2.6 billion by 2032, a 7.3% CAGR. Acumen found IVIg held the largest drug-class share in 2022, North America dominated by region and Asia-Pacific is the fastest-growing region. Its base-year figures predate the recent wave of subcutaneous biologics, so the shift toward self-injected therapies like Klygefa is a factor to watch in future updates.
FAQ
What is Klygefa used for?
Klygefa (gefurulimab-gaks) is approved in the U.S. to treat adults with generalized myasthenia gravis who are anti-AChR antibody positive.
How often is Klygefa given?
After a weight-based loading dose on day 1, patients self-inject a weight-based dose once a week starting on day 8, using an autoinjector.
How is Klygefa different from Soliris and Ultomiris?
All three block complement C5, but Soliris and Ultomiris are IV infusions every two to eight weeks, while Klygefa is a weekly under-the-skin injection given at home.
Does Klygefa require a meningococcal vaccine?
Yes. Patients must be vaccinated at least two weeks before the first dose, and the drug is only available through a REMS safety program.
Follow more U.S. regulatory decisions in our FDA approvals section.
Sources: AstraZeneca US press release (16 Nov 2026); PREVAIL trial, JAMA Neurology. Market data: Acumen Research and Consulting. This article is for information only and is not medical advice. Last updated 17 November 2026.

[…] Myqorzo MAPLE-HCM Label Update: Aficamten Beats Metoprolol as First-Line HCM Option WHO Antimicrobial Resistance Survey: 173 Countries Have Plans, Only 42 Fund Them Igalmi At-Home Approval: FDA Clears First Self-Treatment for Psychiatric Agitation Povofortay EU Approval: First Once-Daily Pill for Hidradenitis Suppurativa Klygefa for Myasthenia Gravis: FDA Approves First Weekly Self-Injected C5 Nanobody […]